Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-CHOICE: P2Y12 Inhibitor Monotherapy vs DAPT after PCI
NCT02079194Unknown
- Sponsor
- Samsung Medical Center
- Start
- Mar 2014
- Primary completion
- Jul 2018
- Countries
- 1
01
Overview
Randomised, open-label trial in coronary artery disease (CAD), sponsored by Samsung Medical Center. Primary endpoint: Major Adverse Cardiocerebral Events at 1 year. Status: unknown.
02
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT02079194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079194.